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1. Introduction
  Oxidative challenge due to generation of free radicals is 
implicated in triggering or transforming non-malignant cells 
to malignant ones either by DNA damage or by modulating 
gene expression. Furthermore, lipid peroxidation is a 
significant characteristic of free radical reactivity which 
results in deleterious effect on cells leading to their 
damage[1].
  Antioxidants like glutathione (GSH)[2], ceruloplasmin (CP)[3], 
antioxidant enzymes like glutathione-S-transferase (GST)[4] and 
lipid peroxidation product malondialdehyde (MDA)[5] have 
been implicated in pathogenesis and prognosis of various 
epithelial malignancies including oral cancer. But their role 
in overall prognosis and cancer recurrence is not clearly 
understood. Therefore, we estimated erythrocytic MDA 
and GSH, plasma CP and total GST in patients with biopsy 
proven oral squamous cell carcinoma and cervical cancer at 
stage Ⅳ(both n=17)  before the onset of treatment and after 
radiotherapy only in cervical cancer patients. Levels were 
compared with their respective prognosis in 2 years.
2. Materials and methods
  Approval for the study was given by the Institutional 
Ethics Committee. Informed consent was obtained from 
each patient before withdrawal of blood sample. All the 
subjects were from Udupi District, Costal Karnataka, India, 
and admitted between Feb 2006 to Jan 2009. 
  Seventeen oral cancer patients who were clinically and 
histologically diagnosed as squamous cell carcinoma of oral 
cavity (stage IV), and underwent same mode of treatment 
were chosen for this study. Patients with oral carcinoma 
were staged using International Union against Cancer 
(UICC) TNM classification (1974) in the study. None of the 
patients with oral cancer had any habit of smoking, tobacco, 
and alcohol consumption. All the cases were treated with 
combination of surgery followed by a course of radiotherapy 
around 23 fractions for 4 to 5 weeks.
  Blood samples were taken from oral cancer patients before 
any definitive treatment using aseptic precautions. Blood 
was collected into ethylenediamine tetraacetate (EDTA) 
bottles and immediately centrifuged under refrigeration at 
3 000 g for 10 minutes. Plasma was carefully removed and 
separated cells were washed thrice with cold phosphate 
buffer containing 0.15 mol/L NaCl, pH 7.4. The erythrocytes 
were suspended in an equal volume of physiological saline 
as 50% cell suspension[6]. Hemolysate was prepared from 
erythrocyte suspension by addition of distilled water 
and was used in the estimation of GSH[7] and MDA[8]. 
Hemoglobin content of erythrocytes was measured by 
cyanmethhemoglobin method[9]. Plasma was used for 
the estimation of CP[10] and total GST[11]. Cervical cancer 
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patients plain blood was collected twice before treatment 
and after radiotherapy and only serum GST was estimated. 
Statistical analysis was carried out using Mann-Whitney 
test and Independent Sample t test.
3. Results
  Sinca all the oral cancer patients were at stage IV, only 
36% of patients had no recurrence. All the above parameters 
namely erythrocytic GSH, MDA, plasma CP and total GST 
were higher in patients with recurrence (Table 1).
  Out of 17 cervical cancer patients who received 
radiotherapy, 9 showed significant decrease [(6.60依0.72) IU/
L VS (4.01依0.68) IU/L] (P<0.01) while 8 showed significant 
increase [(5.46依0.66) IU/L VS (6.67依0.78) IU/L] (P<0.01) in 
post radiotherapy GST as compared to pre treatment values, 
respectively. These patients were followed up for two years 
and 71% with significant increase in post radiotherapy 
values had relapse of cancer within 2 years where as 66% of 
those with significant decrease had no evidence of relapse.
Table 1 
Comparison of GSH, CP, MDA and GST in oral cancer patients (Mean依SD). 
Parameter GSH (mg/grHb) CP (mg/dL) MDA (nM/grHb) GST (IU/L)
Recurrent (n = 9) 5.51依3.76 38.88依26.70 4.53依2.22 6.45依3.97
Non-recurrent (n = 5) 5.26依2.63 32.05依21.55 3.97依1.51 3.30依2.20
4. Discussion
  The generation of reactive oxygen radicals in mammalian 
cells profoundly affects numerous critical cellular functions, 
and the absence of efficient cellular detoxification 
mechanisms which remove these free radicals can result 
in several diseases. Reactive oxygen species (ROS) are 
tumorogenic by virtue of their ability to increase cell 
proliferation, survival, cellular migration, and also by 
inducing DNA damage, leading to genetic lesions that 
initiate tumorogenicity and sustain subsequent tumor 
progression[1].  
  Enhanced antioxidant capacity of tumor tissues make them 
less susceptible to oxidative stress conferring specific growth 
advantage[12] which has also been implicated in radio/chemo 
resistance leading to tumor recurrence[4,13]. In this study 
even though all the oral cancer  patients were at stage IV, 
some had no recurrence. Then we grouped them into good 
and bad responders. It is observed that patients with higher 
pretreatment levels of GST, GSH, and CP had recurrence 
within 2 years after treatment. Radiation is known to induce 
oxidative stress, which may cause induction of antioxidant 
status of irradiated tumor[13]. This may influence the 
radiation response in some selected human carcinoma 
cells[14]. Our results show the association of GST level and 
radiation response in cervical cancer patients. This indicates 
high levels of the antioxidant produced in these cancer 
patients as an adaptive response to combat the free radicals, 
which are generated as a consequence of high metabolic 
rate, then to protect these cells against the cytotoxic effects 
of radio/chemotherapy and hence leading to recurrence. 
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